Dichlorvos (DDVP) Risk Characterization Document - California ...
Dichlorvos (DDVP) Risk Characterization Document - California ... Dichlorvos (DDVP) Risk Characterization Document - California ...
Table 12. Selected no-observed-effect levels (NOELs) and lowest-observed-effect levels (LOELs) of DDVP from reproductive toxicity studies. Plasma ChE a RBC ChE a Brain ChE a Other Effects Species Route Duration NOEL LOEL % C NOEL LOEL % C NOEL LOEL % C NOEL LOEL Effects Ref. b (mg/kg-day) (mg/kg-day) (mg/kg-day) (mg/kg-day) Rat water daily c (range finding) females and - 3 48-66% - 3 58-61% - 3 54-93% - 1 males F 0 females F 0 - - - - - - 11-17 22-44 maternal-reduced body weight gain, food consumption females F 0 - - - - - - 24 41 maternal- tremors (first on day 7) fetal F 1 - - - - - - 11 22 fetal-cholinergic signs Rat water daily c,d 2.7 9.5 parental 2* -decreased fertility, females F 0 1.1 4.6 45%
G. DEVELOPMENTAL TOXICITY Summary: DDVP, given by oral or inhalation routes, was not teratogenic in rats, mice, or rabbits. Cholinergic signs (tremors, ataxia, diarrhea, and other effects) were observed in the pregnant rats and rabbits. Selected studies are presented in Table 13. Gavage - Rat DDVP (97% purity; 0, 0.1, 3.0, or 21.0 mg/kg-day) was given to Sprague-Dawley pregnant rats (25/group) by gavage once daily from gestational days 6 to 15 (Tyl et al., 1991a). Systemic toxicity was observed only in the high dose group. There was a significant (p @ 0.05) reduction in the maternal body weight as the mean maternal weight gain was 66% of control value during the treatment period. Cholinergic signs observed were tremors and excitability. Tremors were observed in the 21.0 mg/kg-day group with the onset within 10-60 minutes after each daily dosing. Other signs of toxicity included prone positioning, hindlimb splay, circling, vocalization, hypoactivity, labored respiration, ear shaking, and coprophagia. Examination of the fetuses showed no significant increases in the incidence of gestational parameters and of individual or pooled external, visceral, skeletal, or total fetal malformations or variations. The incidence (18 fetuses/8 litters) of enlarged lateral ventricles of the cerebrum in the fetuses of the 21.0 mg/kg-day was slightly higher, though not statistically significant, than that (9 fetuses/5 litters) for the control group. The NOELs were 3.0 mg/kg-day for maternal toxicity and greater than 21.0 mg/kg-day for developmental toxicity. This study was considered acceptable to DPR according to FIFRA guidelines. Intraperitoneal - Rat Pregnant Sherman rats (6/group) were given a single dose of DDVP (purity not stated, 15 mg/kg) by intraperitoneal injection on day 11 after insemination (Kimbrough and Gaines, 1968). On day 20 of pregnancy, the fetuses were examined. Of the 41 fetuses examined, omphalocele was noted in 3 fetuses. There were no significant differences in the average weight gain of the dams, average number of fetuses per litter, average number of resorptions, average weight of fetuses, and average weight of placenta. The report noted that a dose of 20 mg/kg DDVP was lethal to pregnant rats. Except for lethality and dam body weights, the report did not include clinical observations. Inhalation - Rat Female rats (Carworth Farm E strain, 9-10/treated group) were exposed to DDVP (>97% purity; at nominal concentrations of 0, 0.25, 1.25, or 6.25 ug/L equivalent to 0, 0.23, 1.15, or 5.75 mg/kg-day) for 23 hours daily by inhalation (Thorpe et al., 1971a). They were treated from day 1 of insemination (pregnancy) to gestation day 20. At the end of the experiment, plasma, erythrocyte, and brain ChE activities of the 1.25 ug/L group were significantly (p
- Page 3 and 4: transmitter of signals from the ner
- Page 5 and 6: Contributors and Acknowledgments Pr
- Page 7 and 8: List of Tables Pages 1. The acute t
- Page 9 and 10: hematocrit) in rats. From studies w
- Page 11 and 12: II. INTRODUCTION The human health r
- Page 13 and 14: food service facilities); hand-held
- Page 15 and 16: G. ENVIRONMENTAL FATE Summary: DDVP
- Page 17 and 18: III. TOXICOLOGY PROFILE Pharmacokin
- Page 19 and 20: Inhalation - Rat Carworth Farm stra
- Page 21 and 22: DIMETHYL PHOSPHATE Oral - Rat Rats
- Page 23 and 24: B. ACUTE TOXICITY Summary: The acut
- Page 25 and 26: Oral - Human One hundred and eight
- Page 27 and 28: Table 1. The acute toxicity of DDVP
- Page 29 and 30: Table 1. The acute toxicity of DDVP
- Page 31 and 32: Table 2. Selected no-observed-effec
- Page 33 and 34: dose-related manner. At a dosage of
- Page 35 and 36: pretreatment levels, respectively.
- Page 37 and 38: Table 3. Selected no-observed-effec
- Page 39 and 40: Gavage - Rat In a study conducted b
- Page 41 and 42: ate (Appendix D) and the assumption
- Page 43 and 44: Gavage - Mouse In a study conducted
- Page 45 and 46: Capsules - Dog DDVP (97.3-99.5% pur
- Page 47 and 48: Table 9. The no-observed-effect lev
- Page 49 and 50: Mice exposed to DDVP by inhalation
- Page 51 and 52: F. REPRODUCTIVE TOXICITY Summary: E
- Page 53: Table 11. The dosages and the inhib
- Page 57 and 58: levels not verified, too few pregna
- Page 59 and 60: H. NEUROTOXICITY Summary: Possible
- Page 61 and 62: IV. RISK ASSESSMENT A. HAZARD IDENT
- Page 63 and 64: Acute Toxicity Inhalation The criti
- Page 65 and 66: ates were not statistically signifi
- Page 67 and 68: In mice, there were dose-related in
- Page 69 and 70: B. EXPOSURE ASSESSMENT The exposure
- Page 71 and 72: The U.S. Department of Agriculture
- Page 73 and 74: Acute Exposure Estimates of potenti
- Page 75 and 76: Table 19. Commodity contribution of
- Page 77 and 78: C. RISK CHARACTERIZATION The potent
- Page 79 and 80: Table 23. The margins of safety for
- Page 81 and 82: Table 25. The margins of safety of
- Page 83 and 84: label between treatment and the ava
- Page 85 and 86: VI. TOLERANCE ASSESSMENT A. BACKGRO
- Page 87 and 88: VII. CONCLUSIONS The toxicological
- Page 89 and 90: Bomhard, E., and M. Rinke, 1994. Fr
- Page 91 and 92: DPR, 1992. Sampling for pesticide r
- Page 93 and 94: Horn, K.-H., B. Teichmann, and T. S
- Page 95 and 96: NTP (National Toxicology Program),
- Page 97 and 98: TAS, 1992a. Exposure 4 . Detailed
- Page 99 and 100: Warf Institute Inc., 1977c. Acute e
- Page 101 and 102: APPENDIX A U.S. ENVIRONMENTAL PROTE
- Page 103 and 104: APPENDIX B Department of Pesticide
G. DEVELOPMENTAL TOXICITY<br />
Summary: <strong>DDVP</strong>, given by oral or inhalation routes, was not teratogenic in rats, mice, or rabbits.<br />
Cholinergic signs (tremors, ataxia, diarrhea, and other effects) were observed in the pregnant rats and<br />
rabbits. Selected studies are presented in Table 13.<br />
Gavage - Rat<br />
<strong>DDVP</strong> (97% purity; 0, 0.1, 3.0, or 21.0 mg/kg-day) was given to Sprague-Dawley pregnant rats<br />
(25/group) by gavage once daily from gestational days 6 to 15 (Tyl et al., 1991a). Systemic toxicity<br />
was observed only in the high dose group. There was a significant (p @ 0.05) reduction in the<br />
maternal body weight as the mean maternal weight gain was 66% of control value during the<br />
treatment period. Cholinergic signs observed were tremors and excitability. Tremors were observed<br />
in the 21.0 mg/kg-day group with the onset within 10-60 minutes after each daily dosing. Other signs<br />
of toxicity included prone positioning, hindlimb splay, circling, vocalization, hypoactivity, labored<br />
respiration, ear shaking, and coprophagia. Examination of the fetuses showed no significant<br />
increases in the incidence of gestational parameters and of individual or pooled external, visceral,<br />
skeletal, or total fetal malformations or variations. The incidence (18 fetuses/8 litters) of enlarged<br />
lateral ventricles of the cerebrum in the fetuses of the 21.0 mg/kg-day was slightly higher, though not<br />
statistically significant, than that (9 fetuses/5 litters) for the control group. The NOELs were 3.0<br />
mg/kg-day for maternal toxicity and greater than 21.0 mg/kg-day for developmental toxicity. This<br />
study was considered acceptable to DPR according to FIFRA guidelines.<br />
Intraperitoneal - Rat<br />
Pregnant Sherman rats (6/group) were given a single dose of <strong>DDVP</strong> (purity not stated, 15 mg/kg) by<br />
intraperitoneal injection on day 11 after insemination (Kimbrough and Gaines, 1968). On day 20 of<br />
pregnancy, the fetuses were examined. Of the 41 fetuses examined, omphalocele was noted in 3<br />
fetuses. There were no significant differences in the average weight gain of the dams, average<br />
number of fetuses per litter, average number of resorptions, average weight of fetuses, and average<br />
weight of placenta. The report noted that a dose of 20 mg/kg <strong>DDVP</strong> was lethal to pregnant rats.<br />
Except for lethality and dam body weights, the report did not include clinical observations.<br />
Inhalation - Rat<br />
Female rats (Carworth Farm E strain, 9-10/treated group) were exposed to <strong>DDVP</strong> (>97% purity; at<br />
nominal concentrations of 0, 0.25, 1.25, or 6.25 ug/L equivalent to 0, 0.23, 1.15, or 5.75 mg/kg-day)<br />
for 23 hours daily by inhalation (Thorpe et al., 1971a). They were treated from day 1 of insemination<br />
(pregnancy) to gestation day 20. At the end of the experiment, plasma, erythrocyte, and brain ChE<br />
activities of the 1.25 ug/L group were significantly (p